Madrigal Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Madrigal Pharmaceuticals 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MDGL

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of therapeutics for metabolic dysfunction-associated steatohepatitis. The company was founded by Rebecca A. 

CEO
William J. Sibold
CEOWilliam J. Sibold
Employees
915
Employees915
Headquarters
West Conshohocken, Pennsylvania
HeadquartersWest Conshohocken, Pennsylvania
Founded
2000
Founded2000
Employees
915
Employees915

MDGL Key Statistics

Market cap
11.62B
Market cap11.62B
Price-Earnings ratio
-39.12
Price-Earnings ratio-39.12
Dividend yield
—
Dividend yield—
Average volume
243.53K
Average volume243.53K
High today
$515.00
High today$515.00
Low today
$501.81
Low today$501.81
Open price
$513.87
Open price$513.87
Volume
259.52K
Volume259.52K
52 Week high
$615.00
52 Week high$615.00
52 Week low
$393.61
52 Week low$393.61

Stock Snapshot

Madrigal Pharmaceuticals(MDGL) stock is priced at $503.96, giving the company a market capitalization of 11.62B. It carries a P/E multiple of -39.12.

On 2026-10-01, Madrigal Pharmaceuticals(MDGL) stock moved within a range of $501.81 to $515.00. With shares now at $503.96, the stock is trading +0.4% above its intraday low and -2.1% below the session's peak.

Trading volume for Madrigal Pharmaceuticals(MDGL) stock has reached 259.52K, versus its average volume of 243.53K.

Over the past 52 weeks, Madrigal Pharmaceuticals(MDGL) stock has traded between a high of $615.00 and a low of $393.61.

Over the past 52 weeks, Madrigal Pharmaceuticals(MDGL) stock has traded between a high of $615.00 and a low of $393.61.

MDGL News

Simply Wall St 5d
How New Headquarters Opening At Madrigal Pharmaceuticals Has Changed Its Investment Story - simplywall.st

...

How New Headquarters Opening At Madrigal Pharmaceuticals Has Changed Its Investment Story - simplywall.st
TipRanks 7d
Madrigal Pharmaceuticals resumed with a Buy at Goldman Sachs

Goldman Sachs resumed coverage of Madrigal Pharmaceuticals (MDGL) with a Buy rating and $704 price target Goldman resumed coverage of the biotechnology sector,...

Analyst ratings

95%

of 21 ratings
Buy
95.2%
Hold
4.8%
Sell
0%

People also own

Based on the portfolios of people who own MDGL. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.